- Home
- ADXN vs ALZN Comparison
ADXN vs ALZN Comparison
Compare ADXN & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- ALZN
- Stock Information
- Founded
- ADXN 2002
- ALZN 2016
- Country
- ADXN Switzerland
- ALZN United States
- Employees
- ADXN N/A
- ALZN N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- ADXN Health Care
- ALZN Health Care
- Exchange
- ADXN Nasdaq
- ALZN Nasdaq
- Market Cap
- ADXN 8.1M
- ALZN 9.0M
- IPO Year
- ADXN N/A
- ALZN 2021
- Fundamental
- Price
- ADXN $8.81
- ALZN $2.40
- Analyst Decision
- ADXN
- ALZN Strong Buy
- Analyst Count
- ADXN 0
- ALZN 1
- Target Price
- ADXN N/A
- ALZN $42.00
- AVG Volume (30 Days)
- ADXN 22.2K
- ALZN 103.3K
- Earning Date
- ADXN 11-10-2025
- ALZN 12-11-2025
- Dividend Yield
- ADXN N/A
- ALZN N/A
- EPS Growth
- ADXN N/A
- ALZN N/A
- EPS
- ADXN N/A
- ALZN N/A
- Revenue
- ADXN $210,347.00
- ALZN N/A
- Revenue This Year
- ADXN $86.57
- ALZN N/A
- Revenue Next Year
- ADXN N/A
- ALZN N/A
- P/E Ratio
- ADXN N/A
- ALZN N/A
- Revenue Growth
- ADXN N/A
- ALZN N/A
- 52 Week Low
- ADXN $6.51
- ALZN $2.06
- 52 Week High
- ADXN $12.05
- ALZN $14.31
- Technical
- Relative Strength Index (RSI)
- ADXN 47.70
- ALZN 44.53
- Support Level
- ADXN $8.50
- ALZN $2.31
- Resistance Level
- ADXN $9.00
- ALZN $2.61
- Average True Range (ATR)
- ADXN 0.50
- ALZN 0.17
- MACD
- ADXN -0.09
- ALZN -0.01
- Stochastic Oscillator
- ADXN 20.95
- ALZN 8.11
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.